13 research outputs found

    From Gettysburg to Townsville, Australia and Back

    Full text link
    I studied abroad in Townsville, AU in the Fall 2014 and had the semester of my life. I am biology major, who has always wanted to pursue a career with animals and I got to run hands on experiments at James Cook University. I collected research on wild rock wallabies, I got Open Water Padi Dive certified and dove throughout Australia and Bali, Indonesia. I got up close with wild sharks, eels, jellyfish, and a variety of tropical fish. I joined the co-ed soccer and disc team. Most importantly, I became friends with amazing people from all over the world

    Genetic studies of abdominal MRI data identify genes regulating hepcidin as major determinants of liver iron concentration

    Get PDF
    Background & Aims: Excess liver iron content is common and is linked to hepatic and extrahepatic disease risk. We aimed to identify genetic variants influencing liver iron content and use genetics to understand its link to other traits and diseases. Methods: First, we performed a genome-wide association study (GWAS) in 8,289 individuals in UK Biobank with MRI quantified liver iron, and validated our findings in an independent cohort (n=1,513 from IMI DIRECT). Second, we used Mendelian randomisation to test the causal effects of 29 predominantly metabolic traits on liver iron content. Third, we tested phenome-wide associations between liver iron variants and 770 anthropometric traits and diseases. Results: We identified three independent genetic variants (rs1800562 (C282Y) and rs1799945 (H63D) in HFE and rs855791 (V736A) in TMPRSS6) associated with liver iron content that reached the GWAS significance threshold (p<5x10-8). The two HFE variants account for ~85% of all cases of hereditary haemochromatosis. Mendelian randomisation analysis provided evidence that higher central obesity plays a causal role in increased liver iron content. Phenome-wide association analysis demonstrated shared aetiopathogenic mechanisms for elevated liver iron, high blood pressure, cirrhosis, malignancies, neuropsychiatric and rheumatological conditions, while also highlighting inverse associations with anaemias, lipidaemias and ischaemic heart disease. Conclusion: Our study provides genetic evidence that mechanisms underlying higher liver iron content are likely systemic rather than organ specific, that higher central obesity is causally associated with higher liver iron, and that liver iron shares common aetiology with multiple metabolic and non-metabolic diseases

    KIR3DS1 directs NK cell-mediated protection against human adenovirus infections

    No full text
    Human adenoviruses (HAdVs) are a major cause for disease in children, in particular after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Currently, effective therapies for HAdV infections in immunocompromised hosts are lacking. To decipher immune recognition of HAdV infection and determine new targets for immune-mediated control, we used an HAdV infection 3D organoid system, based on primary human intestinal epithelial cells. HLA-F, the functional ligand for the activating NK cell receptor KIR3DS1, was strongly up-regulated and enabled enhanced killing of HAdV5-infected cells in organoids by KIR3DS1(+) NK cells. In contrast, HLA-A and HLA-B were significantly down-regulated in HAdV5-infected organoids in response to adenoviral E3/glycoprotein 19K, consistent with evasion from CD8(+) T cells. Immunogenetic analyses in a pediatric allo-HSCT cohort showed a reduced risk to develop severe HAdV disease and faster clearance of HAdV viremia in children receiving KIR3DS1(+)/HLA-Bw4(+) donor cells compared with children receiving non-KIR3DS1(+)/HLA-Bw4(+) cells. These findings identify the KIR3DS1/HLA-F axis as a new target for immunotherapeutic strategies against severe HAdV disease

    Simulated mark-recovery for spatial assessment of a spiny lobster (Panulirus argus) fishery

    No full text
    •We simulate scenarios representing spiny lobster distribution at Glover's Reef Marine Reserve, Belize.•We examine how no-take reserves bias stock assessments that rely solely on fishery-dependent data.•We evaluate whether a mark-recovery design can be robust to uncertainty about transfer rates between fished and non-fished areas.•Fishing mortality can usually be accurately estimated by mark-recovery without prior knowledge of fish transfer rates.Marine reserves are becoming widely implemented along with conventional fisheries controls as integrated approaches to fisheries management. The restricted spatial distribution of fishing effort, relative to the spatial distribution of fish stocks that may be partially protected by marine reserves, often necessitates spatial considerations in the design of monitoring and stock assessment. Simulation modeling was used to evaluate whether a mark-recovery design could be used to accurately estimate fishing mortality rates without information about movement rates being available to the assessment procedure. A spatially-explicit individual-based simulation was developed with environmental characteristics of Glover's Reef Marine Reserve, Belize and with biological characteristics of a fished population of Caribbean spiny lobster (Panulirus argus). Accuracy of fishing mortality estimates depended on whether these estimates were calculated for the fished area only or for the entire stock. Stock-wide fishing mortality estimates could usually be obtained that were robust to uncertainty about dispersive movement. We discuss results in the context of managing fisheries based on the status of fished areas alone or on the entire stock and discuss the necessity for information about fish movement for accurate assessment of stocks managed using marine reserves

    Effect of allopurinol in addition to hypothermia treatment in neonates for hypoxic-ischemic brain injury on neurocognitive outcome (ALBINO): Study protocol of a blinded randomized placebo-controlled parallel group multicenter trial for superiority (phase III)

    No full text
    Background: Perinatal asphyxia and resulting hypoxic-ischemic encephalopathy is a major cause of death and long-term disability in term born neonates. Up to 20,000 infants each year are affected by HIE in Europe and even more in regions with lower level of perinatal care. The only established therapy to improve outcome in these infants is therapeutic hypothermia. Allopurinol is a xanthine oxidase inhibitor that reduces the production of oxygen radicals as superoxide, which contributes to secondary energy failure and apoptosis in neurons and glial cells after reperfusion of hypoxic brain tissue and may further improve outcome if administered in addition to therapeutic hypothermia. Methods: This study on the effects of ALlopurinol in addition to hypothermia treatment for hypoxic-ischemic Brain Injury on Neurocognitive Outcome (ALBINO), is a European double-blinded randomized placebo-controlled parallel group multicenter trial (Phase III) to evaluate the effect of postnatal allopurinol administered in addition to standard of care (including therapeutic hypothermia if indicated) on the incidence of death and severe neurodevelopmental impairment at 24 months of age in newborns with perinatal hypoxic-ischemic insult and signs of potentially evolving encephalopathy. Allopurinol or placebo will be given in addition to therapeutic hypothermia (where indicated) to infants with a gestational age ≥ 36 weeks and a birth weight ≥ 2500 g, with severe perinatal asphyxia and potentially evolving encephalopathy. The primary endpoint of this study will be death or severe neurodevelopmental impairment versus survival without severe neurodevelopmental impairment at the age of two years. Effects on brain injury by magnetic resonance imaging and cerebral ultrasound, electric brain activity, concentrations of peroxidation products and S100B, will also be studied along with effects on heart function and pharmacokinetics of allopurinol after iv-infusion. Discussion: This trial will provide data to assess the efficacy and safety of early postnatal allopurinol in term infants with evolving hypoxic-ischemic encephalopathy. If proven efficacious and safe, allopurinol could become part of a neuroprotective pharmacological treatment strategy in addition to therapeutic hypothermia in children with perinatal asphyxia. Trial registration: NCT03162653, www.ClinicalTrials.gov, May 22, 2017
    corecore